The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-07 and is reviewed periodically as new material appears.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Aluminum salts or gels are added as adjuvants. Adjuvants are added to promote an earlier, more potent response, and more persistent immune response to the vaccine; they allow for a lower vaccine dosage. Antibiotics are added to some vaccines to prevent the growth of bacteria during production and storage of the vaccine. Egg protein is present in the influenza vaccine and yellow fever vaccine as they are prepared using chicken eggs. Other proteins may be present. Formaldehyde is used to inactivate bacterial products for toxoid vaccines. Formaldehyde is also used to inactivate unwanted viruses and kill bacteria that might contaminate the vaccine during production. Monosodium glutamate (MSG) and 2-phenoxyethanol are used as stabilizers in a few vaccines to help the vaccine remain unchanged when the vaccine is exposed to heat, light, acidity, or humidity. Thiomersal is a mercury-containing antimicrobial that is added to vials of vaccines that contain more than one dose to prevent contamination and growth of potentially harmful bacteria. Due to the controversy surrounding thiomersal, it has been removed from most vaccines except multi-use influenza, where it was reduced to levels so that a single dose contained less than a microgram of mercury, a level similar to eating ten grams of canned tuna.
So, once they had synthesized L-photo-methionine, the yield was 32%, much higher (by six times) the original synthesis. It was used then (with a protection group Fmoc on the amine) which that product underwent more synthetic steps to study if an amino-acid cross linker and a post-translational modification (PTM) could be introduced to the same protein site specifically to capture a covalent interaction of the amino-acid is dependent on the PTM. PTM's regulate protein-protein interactions that have characteristics that are transient and substoichiometric; making these difficult to detect by standard methods. So, in order to see if it would work, the MH2 domain of Smad2 was used because this signaling protein is known to form stable homo-trimers once they come into contact with receptor-phosphorylated serine residues. Expression protein ligation (known as EPL) was used to synthesize to form Smad2-MH2-CSpSM-photo-Met (1). The product was studied with the cross-linker (photo-Met) against a control protein: HA-MH2-CSpSMpS (this lacks photo-methionine, 2) using SDS-PAGE and western blotting using anti-HA antibody. 1 had generated two major cross-linked species that have molecular weight consistent with a dimer and trimer of Smad2-SH2. Without that cross-linker, the dimer and trimer were barely detected in the non-irradiated 1, and in 2 before and after UV irradiation. Proving that l-photo-methionine can be used with EPL and could be used to determine a transient MH2-MH2 interaction that was dependent on a PTM.
He said: "These were all economical ways of doing storytelling with the architecture—which was my whole obsession. The narrative had to be baked into the corridors." Within a month of the cabal's formation, the other team members started detailed game development, and within another month began playtesting through Sierra. The cabal was intimately involved with playtesting, monitoring the player but otherwise not interacting. They noted any confusion or inability to solve a game's puzzles and made them into action items to be fixed on the next iteration. Later, with most of the main adjustments made, the team included means to benchmark players' actions. They then collected and interpreted statistically to fine-tune levels further. Between the cabal and playtesting, Valve identified and removed parts that proved unenjoyable. Birdwell said that while there were struggles at first, the cabal approach was critical for Half-Life's success, and was reused for Team Fortress 2 from the start. Much of the detail of Half-Life's development has been lost. According to Valve employee Erik Johnson, two or three months before release, their Visual SourceSafe source control system "exploded". Logs of technical changes from before the final month of development were lost, and code had to be recovered from individual computers. The revised version of Half-Life shown at E3 1998 received the Game Critics Awards for "Best PC Game" and "Best Action Game".
=== Overview of European experience in nuclear partitioning === A lot of research funded by the European Commission is being devoted to hydrometallurgical processes for the partitioning and transmutation of trivalent actinides (An). These research programs have first led to multicycle processes, secondly to the development of simplified and innovative processes. The hydrometallurgical partitioning consists of two relevant steps: extraction and stripping. In the first step the organic phase, containing the extracting ligand dissolved in a suitable solvent, is contacted with the aqueous phase coming from the dissolution of the irradiated fuel. The solutes present in the aqueous phase are extracted by a complexation reaction with the extracting agent and transferred into the organic phase in which the formed complexes are soluble. The second step, known as stripping, is obtained by reversing the complexation reaction, where the solutes are back-extracted into another aqueous solution usually different in acidity compared to the previous one. The main goal is to develop reliable and affordable industrial separation processes by lipophilic and hydrophilic ligands to selectively extract minor actinides from the (3–4) M acidic target waste downstream of the PUREX process, but with the more challenging goal to minimize the amount of solid secondary waste.
==== Small modular reactors ==== In November 2020, Ontario Power Generation (OPG) announced plans to build a small modular reactor (SMR) at Darlington Nuclear Generating Station. OPG will work with GE Vernova Hitachi Nuclear Canada to build the SMR. On December 2, 2022, Ontario Power Generation officially broke ground on the Darlington SMR (Darlington B) project. The first unit to be constructed is a GVH BWRX-300 unit. Construction started in May 2025, with the reactor expected to come online in 2030.
Sources: en.wikipedia.org
Alberto E. Paniz-Mondolfi (born April 12, 1976) is a Venezuelan pathologist, epidemiologist, and molecular medicine researcher. Currently he is a pathologist and assistant professor in New York City and is affiliated with multiple hospitals in the area, including Mount Sinai Morningside and Mount Sinai West Hospitals and Mount Sinai Hospital. Also, he is the Academic Director and Founder of The Venezuelan Science Incubator (incubadorave.org), a group focused on infectious diseases research and awareness based in Venezuela.
== Examples == The diabetic drug Liraglutide, incorporates a lipid chain to extend plasma circulation and prolong bio-availability. Liraglutide is a GLP-1 agonist drug that self-assembles into an alpha-helical structure, and it requires once a day administration. Lipid conjugation of a palmitoyl chain to a lysine residue at position 26 of Liraglutide results in an extended half-life (around 13–14 hours) in the blood. This is due to the palmitoyl chain allowing non covalent binding to albumin, which delays proteolytic attack by DPP IV and also rapid renal clearance. Furthermore, the addition of the lipid chain could further prolong half-life by sterically hindering the DPP IV enzyme from degradation. Another peptide known to self-assemble is the octapeptide Lanreotide. This compound is a synthetic analogue of the peptide hormone somatostatin and it is used to treat acromegaly (a condition where the body produced too much growth hormone). In water, Lanreotide self-assembles into monodisperse liquid crystalline nanotubes. The nanotubes are made up of dimers that self-assemble into a 2D crystal, which is held together by lateral chain interactions, and also by anti-parallel ß-sheets. Further insight into how self-assembly and peptide hormones are related has been provided by studies on self-assembling amyloid structures formed by peptide hormones and neuropeptides. Peptide hormones and neuropeptides form dense-cored aggregates that pack into dense-core vesicles (DCVs), which are used to temporarily store peptide messengers in secretory cells.
Recent evidence has suggested that this macrophage activation may involve a phenomenon known as innate immune memory. Also known as trained immunity, innate immune memory is the innate immune system's ability, upon exposure to oxLDL or other atherogenic stimuli, to undergo epigenetic and metabolic reprogramming, leading to a hyperaugmented immune response following a secondary, non-specific restimulation. Under the microscope, the lesion now appears as a fatty streak. Foam cells eventually die and further propagate the inflammatory process. In addition to these cellular activities, there is also smooth muscle proliferation and migration from the tunica media into the intima in response to cytokines secreted by damaged endothelial cells. This leads to the formation of a fibrous capsule covering the fatty streak. Intact endothelium can prevent this smooth muscle proliferation by releasing nitric oxide.
Traditionally in composite science a strong interface between the matrix and filler is required to achieve favorable mechanical properties. If this is not the case, the phases tend to separate along the weak interface and makes for very poor mechanical properties. In a MCC composite however this is not the case, if the interaction between the filler and matrix is stronger than the filler-filler interaction the mechanical strength of the composite is noticeably decreased. Difficulties in natural fiber nanocomposites arise from dispersity and the tendency small fibers to aggregate in the matrix. Because of the high surface area to volume ratio the fibers have a tendency to aggregate, more so than in micro-scale composites. Additionally secondary processing of collagen sources to obtain sufficient purity collagen micro fibrils adds a degree of cost and challenge to creating a load bearing cellulose or other filler based nanocomposite.
Sources: en.wikipedia.org
== Function == Collagen VI plays many different roles in the cell depending on which tissue in which it is expressed. ColVI maintains a mechanical function in the cell, which is typical of most types of Collagen, by providing stability and structural support in the ECM. ColVI allows muscle cells to connect with the ECM by interacting with perlecan in the basal lamina. ColVI also functions as a cytoprotective agent:
== Dysprosium-165 == The radioactive isotope 165Dy, with a half-life of 2.332 hours, has radiopharmaceutical uses in radiation synovectomy of the knee. It had been previously performed with colloidal-sized particles containing longer-lived isotopes such as 198Au and 90Y. The major problem with the usage of those isotopes was radiation leakage out of the knee. 165Dy, with its shorter half-life and thus shorter period of potential radiation leakage, is more suitable for the procedure.
Since 28 February 2026, the United States and Israel have been at war with Iran and its regional allies. The war follows the Twelve-Day War in June 2025 and sporadic fighting during the Middle Eastern crisis sparked by the Gaza war (2023–present). Amid ongoing US–Iran negotiations regarding Iran's nuclear program, the war began when the US and Israel conducted hundreds of air strikes on targets across Iran, including strikes that assassinated Supreme Leader Ali Khamenei alongside several other Iranian officials. American rationale for initiating the war included regime change, preventing Iran from obtaining a nuclear weapon, a response to the massacre of several if not tens of thousands of anti-government protesters in Iran, and taking Iran's oil and gas resources. Critics have rejected these justifications, maintaining that the attack initiated a war of aggression, in violation of international law. Later war goals focused on nuclear negotiations and reopening the Strait of Hormuz. Public opinion was opposed to the war in the United States and in many other countries, leading to widespread disapproval for Donald Trump and declining views of the US and Israel around the world. The war was preceded in January–February 2026 by the largest US military buildup in the region since the 2003 invasion of Iraq.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.